BDP/FF/GB

DRUG2 trials

Sponsors

Chiesi Farmaceutici S.p.A.

Conditions

Chronic Obstructive Pulmonary Disease

Phase 3

Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease

CompletedNCT01911364

Chiesi Farmaceutici S.p.A.Chronic Obstructive Pulmonary Disease

Start: 2014-01-31End: 2016-03-31Updated: 2021-10-29

Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT02467452

Chiesi Farmaceutici S.p.A.Chronic Obstructive Pulmonary Disease

Start: 2015-05-31End: 2017-01-31Updated: 2021-10-29

Related Papers

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial.

2020-06-0510 citations

Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.

2020-05-2930 citations

<p>Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA</p>

International Journal of COPD2019-02-0121 citations

Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.

2017-04-03278 citations